Women's perspectives on counseling about risks for medication-induced birth defects

Aimee K. Santucci, Melanie A. Gold, Aletha Y. Akers, Sonya Borrero, Eleanor Schwarz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

PURPOSE: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs). METHODS: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus. RESULTS: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP. CONCLUSIONS: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.

Original languageEnglish (US)
Pages (from-to)64-69
Number of pages6
JournalBirth Defects Research Part A - Clinical and Molecular Teratology
Volume88
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Counseling
Health Personnel
Pregnancy
Privacy
Women's Health
Focus Groups
Consensus
Fetus
Health

Keywords

  • Birth defects
  • Contraception
  • Counseling
  • Medications
  • Qualitative
  • Teratogens

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Developmental Biology

Cite this

Women's perspectives on counseling about risks for medication-induced birth defects. / Santucci, Aimee K.; Gold, Melanie A.; Akers, Aletha Y.; Borrero, Sonya; Schwarz, Eleanor.

In: Birth Defects Research Part A - Clinical and Molecular Teratology, Vol. 88, No. 1, 01.01.2010, p. 64-69.

Research output: Contribution to journalArticle

Santucci, Aimee K. ; Gold, Melanie A. ; Akers, Aletha Y. ; Borrero, Sonya ; Schwarz, Eleanor. / Women's perspectives on counseling about risks for medication-induced birth defects. In: Birth Defects Research Part A - Clinical and Molecular Teratology. 2010 ; Vol. 88, No. 1. pp. 64-69.
@article{9cb8335cd21644938640e57e62a7c19f,
title = "Women's perspectives on counseling about risks for medication-induced birth defects",
abstract = "PURPOSE: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs). METHODS: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus. RESULTS: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP. CONCLUSIONS: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.",
keywords = "Birth defects, Contraception, Counseling, Medications, Qualitative, Teratogens",
author = "Santucci, {Aimee K.} and Gold, {Melanie A.} and Akers, {Aletha Y.} and Sonya Borrero and Eleanor Schwarz",
year = "2010",
month = "1",
day = "1",
doi = "10.1002/bdra.20618",
language = "English (US)",
volume = "88",
pages = "64--69",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Women's perspectives on counseling about risks for medication-induced birth defects

AU - Santucci, Aimee K.

AU - Gold, Melanie A.

AU - Akers, Aletha Y.

AU - Borrero, Sonya

AU - Schwarz, Eleanor

PY - 2010/1/1

Y1 - 2010/1/1

N2 - PURPOSE: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs). METHODS: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus. RESULTS: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP. CONCLUSIONS: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.

AB - PURPOSE: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs). METHODS: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus. RESULTS: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP. CONCLUSIONS: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed.

KW - Birth defects

KW - Contraception

KW - Counseling

KW - Medications

KW - Qualitative

KW - Teratogens

UR - http://www.scopus.com/inward/record.url?scp=75749141367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749141367&partnerID=8YFLogxK

U2 - 10.1002/bdra.20618

DO - 10.1002/bdra.20618

M3 - Article

C2 - 19637252

AN - SCOPUS:75749141367

VL - 88

SP - 64

EP - 69

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 1

ER -